SOLV as reported
Solventum reported $8.31B of revenue over the trailing twelve months, −0.93% on the year before. 11 reported series are charted on this page, each one as filed.
$8.31B
Revenue, trailing twelve months · to Q2 2026 · −0.93% against the twelve months before
- Net Income
- $1.43B
Net Income · +277% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$118M
Free Cash Flow · −180% year on year · trailing twelve months to Q2 2026
- Op Margin
- 25%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $8.31B | −0.93% | Q2 2026 |
| Net Income | $1.43B | +277% | Q2 2026 |
| EPS | $8.17 | +276% | Q2 2026 |
| Gross Margin | 55% | n/a | Q2 2026 |
| Op Margin | 25% | n/a | Q2 2026 |
| Net Margin | 17% | n/a | Q2 2026 |
| ROE | 30% | n/a | Q2 2026 |
| ROA | 11% | n/a | Q2 2026 |
| ROIC | 18% | n/a | Q2 2026 |
| Free Cash Flow | −$118M | −180% | Q2 2026 |
| P/E | 11.2 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Solventum (SOLV) - Revenue & ProfitRevenue & ProfitSolventum (SOLV)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Medical Instruments & Supplies
Ranks #5 of 27 by Smart Score